Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2017 (2017), Article ID 5640186, 4 pages
https://doi.org/10.1155/2017/5640186
Case Report

A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy

1Department of Pneumology, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Germany
2Drug Commission of the German Medical Association, Herbert-Lewin-Platz 1, Berlin, Germany
3Department of Radiology, HELIOS Klinikum Emil von Behring, Berlin, Germany
4Diagnostic Radiology, Thoracic Imaging, Bismarckstr 45-47, Berlin, Germany
5Institute of Pathology, HELIOS Klinikum Emil von Behring, Berlin, Germany
6Onkologie Seestrasse, Seestr. 64, 13347 Berlin, Germany

Correspondence should be addressed to Torsten T. Bauer

Received 26 June 2017; Revised 18 September 2017; Accepted 4 October 2017; Published 10 November 2017

Academic Editor: Kaiser Jamil

Copyright © 2017 Sven Jungmann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U.S. Food and Drug Administration, Highlights of prescribing information, Reference ID: 3694103, 2016, http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205552s002lbl.pdf.
  2. M. Mahmoudi, V. Murthy, J. Suh, A.-d. Bradshaw, and M. Sloance, “Ibrutinib-induced rapidly progressive inflammatory pneumonitis,” in Proceedings of the American Thoracic Society International Conference on C51 Toxic Ingestions and Exposure, Denver, CO, USA, May 2015.
  3. A. R. Mato, P. Islam, C. Daniel et al., “Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia,” Blood, vol. 127, no. 8, pp. 1064–1067, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Camus, The Drug-Induced Respiratory Disease Website, Department of Pulmonary Medicine and Intensive Care, University Hospital, Dijon, France, 2016.
  5. I. E. Ahn, T. Jerussi, M. Farooqui, X. Tian, A. Wiestner, and J. Gea-Banacloche, “Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib,” Blood, vol. 128, no. 15, pp. 1940–1943, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Z. H. Farooqui, J. Valdez, S. Martyr et al., “Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial,” Lancet Oncology, vol. 16, no. 2, pp. 169–176, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. C. S. Link, R. Teipel, F. Heidenreich et al., “Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation,” Bone Marrow Transplantion, vol. 51, no. 6, pp. 793–798, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Tobinai, M. Ogura, K. Ishizawa et al., “Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies,” International Journal of Hematology, vol. 103, no. 1, pp. 86–94, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. M. L. Wang, K. A. Blum, P. Martin et al., “Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results,” Blood, vol. 126, no. 6, pp. 739–745, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. J. C. Byrd, R. R. Furman, S. E. Coutre et al., “Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib,” Blood, vol. 125, no. 16, pp. 2497–2506, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. S. O'Brien, J. A. Jones, S. E. Coutre et al., “Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study,” Lancet Oncology, vol. 17, no. 10, pp. 1409–1418, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. Drug Commission of the German Medical Association, Extract from the Adverse Effect Database, Drug Commission of the German Medical Association, 2016.
  13. M. L. Wang, S. Rule, P. Martin et al., “Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma,” New England Journal of Medicine, vol. 369, no. 6, pp. 507–516, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. J. C. Byrd, J. R. Brown, S. O'Brien et al., “Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia,” New England Journal of Medicine, vol. 371, no. 3, pp. 213–223, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Nishino, E. N. Boswell, H. Hatabu, I. M. Ghobrial, and N. H. Ramaiya, “Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenström macroglobulinemia as a Paradigm,” Oncologist, vol. 20, no. 9, pp. 1077–1083, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Iacovelli, A. Palazzo, S. Mezi, F. Morano, G. Naso, and E. Cortesi, “Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials,” Acta Oncologica, vol. 51, no. 7, pp. 873–879, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. R. R. Furman, J. P. Sharman, S. E. Coutre et al., “Idelalisib and rituximab in relapsed chronic lymphocytic leukemia,” New England Journal of Medicine, vol. 370, no. 11, pp. 997–1007, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. P. M. Barr, G. B. Saylors, E. Forbes Spurgeon et al., “Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL),” in ASCO Annual Meeting Proceedings, Chicago, IL, USA, May–June 2014.
  19. Y. Kawakami, N. Inagaki, S. Salek-Ardakani et al., “Regulation of dendritic cell maturation and function by Bruton’s tyrosine kinase via IL-10 and Stat3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 1, pp. 153–158, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Ní Gabhann, E. Hams, S. Smith et al., “Btk regulates macrophage polarization in response to lipopolysaccharide,” PLoS ONE, vol. 9, no. 1, article e85834, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. J. J. Gagnier, D. Riley, D. G. Altman, D. Moher, H. Sox, and G. S. Kienle, “The CARE guidelines: consensus-based clinical case reporting guideline development,” Deutsches Ärzteblatt International, vol. 110, no. 37, pp. 603–608, 2013. View at Publisher · View at Google Scholar · View at Scopus